Competition for IMU?, page-27

A great outcome so far for those 12 but we can't compare it with our PD1-Vaxx. They used GSK's synthetically manufactured monoclonal T-cell PD1 antibody that has the ability to do the job for the immune system but is not able to trigger the immune system like IMU's B-cell polyclonal PD1 antigen, manufactured by the patients own immune system. It needs to be seen what happens to those patients LT, the cancer could come back, while in IMU's patient the immune system gets activated to take care of any re-occurrence. In case of an immune system too weak to fully respond a combo would be desirable as some already pointed out

Anyway, competition will have to be considered once IMU is selling drugs, until then anything that helps, regardless who developed it, is great.

But there are always some people who try to question IMU's achievements.

GLTA